CryoCath announces 2007 fourth quarter and fiscal year end financi... (1830 Forgiveness of employee share pu...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

CryoCath announces 2007 fourth quarter and fiscal year end financial results

Date:12/17/2007

1,830

Forgiveness of employee share purchase loan - 233,069

Accretion in balance of sale (58,955) -

Unrealized loss on foreign exchange

embedded derivatives 41,175 -

Unrealized foreign exchange loss 617,868 36,321

-------------------------------------------------------------------------

(20,269,301) (19,825,409)

Net change in non-cash working capital

balances relating to operations (note 20) 5,368,087 1,603,942

Decrease in net investments in leases 5,967 61,311

Increase in deferred revenue 193,697 309,049

-------------------------------------------------------------------------

Cash flows related to operating activities (14,701,550) (17,851,107)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Net proceeds from sale of surgical portfolio 19,755,918 -

Proceeds upon maturity of short-term

investments 6,616,907 45,709,482

Acquisition of short-term investments (16,258,558) (25,980,051)

Increase in cash subject to restrictions (1,312,500) -

Acquisition of intellectual property (379,282) (509,442)

Acquisition of property, plant, and equipment (1,248,394) (1,674,827)

Increase in consoles at customers' premises (1,905,872) (1,362,761)

-------------------------------------------------------------------------

Cash flows related to investing activities 5,268,219 16,182,401

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Issuance of common shares 36
'/>"/>

SOURCE CryoCath Technologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results

Post Your Comments:

(Date:12/17/2009)... Good Samaritan Hospital is changing the way ... the launch of the Good Samaritan Hospital Women,s Center ... designed to help treat two common medical problems - ... the bladder, uterus or rectum (pelvic organ prolapse). Three ... leakage and one out of three may experience pelvic ...

(Date:12/17/2009)... National Council on Disability (NCD) will conduct its ... Westheimer, Houston, TX, beginning at 8:30 a.m. on Tuesday, ... Thursday, January 21, 2010. This meeting is open to ... to hear from communities around the country on what ... This meeting will provide another opportunity for that exchange. ...

(Date:12/17/2009)... Data from a recent Thomson Reuters study show that ... papers in 1998 to nearly 112,000 in 2008. ... 2% of the biomedical literature, has evaluated more than ... While only 27 Chinese-authored papers were selected in 2004, ... set to be even higher in 2009. , Jane ...

(Date:12/17/2009)... MA Brandeis University selected Jay and Maureen Neitz, the ... use of gene therapy to treat vision disorders, as ... in Vision Sciences. , The award is funded by ... gift from Brandeis graduates Jay Pepose ,75 and Susan ... graduate research fellowships in vision science. , The Neitzes, ...

(Date:12/17/2009)... The SMARTROLLER®, from OPTP is a uniquely designed, extremely resilient, ... that is flatter and one side that is rounder, making ... , ... Minneapolis, MN (PRWEB) December 17, ... uniquely designed, extremely resilient, ‘two-in-one’ foam roller. This patented foam ...

Breaking Medicine News(10 mins):Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2 Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3 Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2 Health News:China rapidly catching up in research impact 2 Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2 Health News:OPTP Introduces the SMARTROLLER 2

[0] Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health [0] National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities [0] China rapidly catching up in research impact [0] Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis [0] OPTP Introduces the SMARTROLLER

... vitally important in the fight against HIV and they ... work, according to a new commentary published today in ... Imperial College London, who are evaluating multiple candidate vaccines ... funding agencies must commit to sharing technology and expertise ...

... still do not know what causes epileptic seizures, but ... closer to solving this puzzle with the help of ... is the first human genetic mutation based mouse model ... The mouse is now helping Dr Steven Petrou and ...

... California seniors finds too few health tests , MONDAY, ... received by vulnerable elderly Medicare, Medicaid patients is barely ... at the University of California, Los Angeles, used quality ... Vulnerable Elders project to look at 43 specific types ...

... Quarter of 2007; Company Prepares for ... Integration of Organon BioSciences, KENILWORTH, ... reported financial results for the third,quarter of 2007 and commented ... the Organon human health business,and Intervet animal health business. ...

... settlement agreement with Teva, TOKYO, BRISTOL, ... Inc. ("Astellas"; headquarters: Tokyo; President and CEO: ... and Teva,Pharmaceutical Industries Ltd. ("Teva" Nasdaq: TEVA) ... with Item Development AB ("Item") and,King have ...

... study finds that survival for elderly patients with lung ... expenditures for lung cancer treatment. The study by Harvard ... Research researchers, published in the December 1, 2007 issue ... Society, finds that average life-expectancy rose by less than ...

Fight against HIV needs local scientists, say researchers Childhood epilepsy research offers new hope for seizure control Most Elderly Don't Get Good Medical Care: Study Schering-Plough Reports Financial Results for Third Quarter of 2007 Adenoscan(R) Patent Lawsuits Settled Spending more for lung cancer treatment did not substantially increase patients' lives

(Date:12/17/2009)... Dec. 17 SpectraScience, Inc., (OTC Bulletin Board: ... Hitchin has issued the following letter to shareholders: ,, ... pleased to announce that through the recent closing of ... undertaking several initiatives critical to ramping our business performance ... additions to our European sales force. We are increasing ...

(Date:12/17/2009)... LOUIS, Dec. 17 Express Scripts, ... the largest pharmacy benefit management companies in ... study that examined the association of seizure ... A-rated anti-epileptic drug formulations. The study found ... drugs, including brand to generic substitution, was ...

(Date:12/17/2009)... RALEIGH, N.C., Dec. 17 Pharmaceutical Institute ... from GeneEd, Inc., a company specializing in life ... advanced e-courses, help expand Pharmaceutical Institute,s already extensive ... Institute is a leading provider of specialized training ... a subsidiary of Campbell Alliance. Financial terms ...

Breaking Medicine Technology:SpectraScience Releases Shareholder Newsletter 2 SpectraScience Releases Shareholder Newsletter 3 SpectraScience Releases Shareholder Newsletter 4 SpectraScience Releases Shareholder Newsletter 5 Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 2 Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 3 Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2 Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3 U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 1 U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 2 U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 3 U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 4 Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel 28R 29 51884 1 Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 1 Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 2 Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 3

[0] SpectraScience Releases Shareholder Newsletter [0] Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity [0] Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.

... and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/,-- ... GSK ),announced today that the U.S. Food and ... for the new drug application for gepirone extended-,release ... with major,depressive disorder. The FDA had previously ...

... Inc.,(Nasdaq: IDMI ) today announced updated results ... trial (DC-MEL-202). The updated results,showed that the investigational ... of immune response and was well tolerated in,patients ... presented during a poster session at the,International Society ...

Other Medicine Technology:Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2 IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 2 IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 3 IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 4

Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients

... a qualitative enzyme immunoassay (EIA) that ... capsid antigen (EBV-VCA), Epstein-Barr early nuclear ... When used in conjunction with Mono-M ... the serodiagnosis of infectious (EBV) mononucleosis ...

... an ELISA method for the qualitative detection of ... (VCA) in human serum. When the VCA IgG ... such as the EBV nuclear antigen (EBNA-1), VCA ... tests, the results can serve as an aid ...

... (Lyme) test is an enzyme ... the qualitative detection of borrelia ... related Borrelia burgdorferi antibodies (IgG, ... in serum as an aid ...

The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...

Medicine Products:

ImmunoDOT Mono G Test ImmunoWELL EBV VCA IgG Test ImmunoDOT Borrelia (Lyme) Test (with Recombinant Protein)ImmunoWELL Borrelia (Lyme) Test

CryoCath announces 2007 fourth quarter and fiscal year end financi...(1830 Forgiveness of employee share pu...),Health